Table 3 Multivariate regression models of daily dose of long-acting insulin analogue DET and GLAR (U/kg)
Model 1 (N-485, Adj R2 = 0.7636) | Model 2 (N-458, Adj R2 = 0.7699) | |||
|---|---|---|---|---|
Coefficient | P-value (t-test) | Coefficient | P-value (t-test) | |
Long-acting insulin analogue used (DET = 0, GLAR = 1) | −0.0010 | 0.9609 | 0.0009 | 0.9687 |
Patient characteristics | ||||
Gender | 0.0522 | 0.0884 | ||
Age | 0.0026 | <.0001 | 0.0019 | 0.0375* |
Height | −0.0031 | 0.0905 | ||
BMI | 0.0082 | <.0001 | 0.0021 | 0.0003* |
HbA1c value | 0.0081 | 0.6428 | ||
Number of years on antidiabetic modification | 0.0014 | 0.7045 | ||
Number of years on DET or GLAR | 0.0067 | 0.0858 | ||
Geography | ||||
North Denmark Region | 0.5190 | 0.1194 | ||
Central Denmark Region | 0.6017 | 0.0705 | ||
Southern Denmark Region | 0.5495 | 0.0986 | ||
Region Sealand | 0.4502 | 0.1766 | ||
Capital region of Denmark | 0.5674 | 0.0860 | ||
Prescriber (GP = ,specialist) | 0.0272 | 0.1806 | ||
Concomitant insulin use (none = 0, at least one other product = 1) | 0.0259 | 0.3303 | ||
Non-insulin antidiabetic medication (none = 0, at least one other product = 1) | 0.0295 | 0.2177 | 0.0278 | 0.0210* |